Targeting of FBN1 or the fibrillin-1 protein may provide a therapeutic avenue for conditions where there is a deficiency of adipose tissue (such as Marfan syndrome and lipodystrophy) and for obesity and type II diabetes, responsible for a major health burden in today's world. The gene discussed is FBN1; the disease is obesity due to melanocortin 4 receptor deficiency.